Abstract
Background: Ketamine is an increasingly popular tool for the treatment of psychiatric disorders. Initially available in controlled studies at academic institutions, it is now being offered widely in the community, but little is known about how treatment is actually being delivered and if there are undetermined safety concerns. The aim of this study is to assess ketamine prescribing practices among clinics across the United States.
Methods: An online survey was sent to all community-based ketamine clinics with publicly available email addresses collected from 4 ketamine clinic databases (n = 484) between September and November 2023. Public ketamine clinic websites (n = 473) were also reviewed for information regarding the credentials of prescribers in June 2024.
Results: A total of 126 (26% response rate) of the clinics responded to the survey request, and 119 were included in analyses. All included respondents (100%) report utilizing ketamine for treatment-resistant depression, with many also prescribing ketamine for treatment naive (72.3%), bipolar (78.9%), and subclinical depression (59.7%) in addition to nondepressive conditions at significant rates. Over 80% of clinics utilize maintenance ketamine treatment, with a substantial portion doing so for prolonged periods. A variety of ketamine formulations are regularly prescribed, and over 40% of clinics provide ketamine for at-home use. Based on website review, fewer than 30% of ketamine clinics reviewed are run by psychiatric physicians and over 25% are run by nonphysician providers.
Conclusions: There is significant variability in ketamine treatment in the community including indications for therapy, duration of treatment courses, formulation of ketamine prescribed, and setting of use. There is a need for increased oversight and more specific practice guidelines to ensure ketamine is being used safely, appropriately, and effectively.
J Clin Psychiatry 2025;86(3):25m15809
Author affiliations are listed at the end of this article.
Members Only Content
This full article is available exclusively to Professional tier members. Subscribe now to unlock the HTML version and gain unlimited access to our entire library plus all PDFs. If you’re already a subscriber, please log in below to continue reading.
References (26)
- Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol. 1990;185(1):1–10. PubMed CrossRef
- Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–354. PubMed CrossRef
- Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–864. PubMed CrossRef
- Burton KW. Time for a National Ketamine Registry, Experts Say. Medscape; 2023. Accessed January 22, 2024. https://www.medscape.com/viewarticle/988310?form=fpf#vp_1
- Esketamine (Spravato). Package insert. Janssen Pharmaceuticals; 2019.
- Zaki N, Chen L, Lane R, et al. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacol. 2023;48(8):1225–1233. PubMed CrossRef
- Smith-Apeldoorn SY, Veraart JK, Spijker J, et al. Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability. Lancet Psychiatry. 2022;9(11):907–921. PubMed CrossRef
- McMullen EP, Lee Y, Lipsitz O, et al. Strategies to prolong ketamine’s efficacy in adults with treatment-resistant depression. Adv Ther. 2021;38(6):2795–2820. PubMed CrossRef
- Swainson J, Klassen LJ, Brennan S, et al. Non-parenteral ketamine for depression: a practical discussion on addiction potential and recommendations for judicious prescribing. CNS Drugs. 2022;36(3):239–251. PubMed CrossRef
- Schak KM, Vande Voort JL, Johnson EK, et al. Potential risks of poorly monitored ketamine use in depression treatment. Am J Psychiatry. 2016;173(3):215–218. PubMed CrossRef
- Landrum RE, Banov MD. The online, at-home ketamine experience: a clinician’s dilemma. Psychiatr Times. 2022;39(10). Accessed September 16, 2024. https://www.psychiatrictimes.com/view/the-online-at-home-ketamine-experience-aclinicians-dilemma
- Peskin E, Gudin J, Schatman ME. Increased demand for ketamine infusions and associated complexities. J Pain Res. 2023;16:295–299. PubMed CrossRef
- Pacilio RM, Lopez JF, Parikh SV, et al. Safe ketamine use and pregnancy: a nationwide survey and retrospective review of informed consent, counseling, and testing practices. J Clin Psychiatry. 2024;85(3):24m15293. PubMed CrossRef
- Du R, Han R, Niu K, et al. The multivariate effect of ketamine on PTSD: systematic review and meta-analysis. Front Psychiatry. 2022;13:813103. PubMed CrossRef
- Feder A, Costi S, Rutter SB, et al. A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Am J Psychiatry. 2021;178(2):193–202. PubMed CrossRef
- Swainson J, McGirr A, Blier P, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L’humeur Et De L’anxiété (Canmat) Concernant L’utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur. Can J Psychiatry. 2021;66(2):113–125. PubMed CrossRef
- Kwan ATH, Lakhani M, Singh G, et al. Ketamine for the Treatment of Psychiatric Disorders: a systematic review and meta-analysis. CNS Spectrums. 2024;29(5):354–361. CrossRef
- Johnston JN, Kadriu B, Kraus C, et al. Ketamine in neuropsychiatric disorders: an update. Neuropsychopharmacol. 2024;49(1):23–40. PubMed CrossRef
- Parikh SV, Lopez D, Vande Voort JL, et al. Developing an IV ketamine clinic for treatment-resistant depression: a primer. Psychopharmacol Bull. 2021;51(3):109–124. PubMed
- Le TT, Cordero IP, Jawad MY, et al. The abuse liability of ketamine: a scoping review of preclinical and clinical studies. J Psychiatr Res. 2022;151:476–496. PubMed CrossRef
- U.S. Food and Drug Administration. Office of Compounding Quality and Compliance. FDA alerts health care professionals of potential risks associated with compounded ketamine nasal spray. Compounding Risk Alerts; 2022. Accessed September 16, 2024. https://www.fda.gov/drugs/human-drugcompounding/fda-alerts-health-care-professionals-potential-risks-associatedcompounded-ketamine-nasal-spray
- U.S. Food and Drug Administration. Office of Compounding Quality and Compliance. FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders. Compounding Risk Alerts; October 2023. Accessed September 16, 2024. https://www.fda.gov/drugs/human-drugcompounding/fda-warns-patients-and-health-care-providers-about-potentialrisks-associated-compounded-ketamine
- Mathai DS, Hull TD, Vando L, et al. At-home, telehealth-supported ketamine treatment for depression: findings from longitudinal, machine learning and symptom network analysis of real-world data. J Affect Disord. 2024;361:198–208. PubMed CrossRef
- American Psychiatric Association (APA), Council on Communications, Ethics Committee. Position Statement on Direct-to-Consumer Pharmaceutical Advertising. APA Official Actions; 2022. Accessed September 16, 2024. https://www.psychiatry.org/getattachment/db80e5a8-0726-4cb1-b591-c42aafb3458a/Position-Direct-to-Consumer-Pharmaceutical-Advertising.pdf
- Crane MA, DiStefano MJ, Moore TJ. False or misleading claims in online direct-to consumer ketamine advertising in Maryland. JAMA Netw Open. 2023;6(11):e2342210. PubMed CrossRef
- Lapidos A, Lopez-Vives D, Sera CE, et al. Patients’ recovery and non-recovery narratives after intravenous ketamine for treatment-resistant depression. J Affect Disord. 2023;323:534–539. PubMed CrossRef
Please sign in or purchase this PDF for $40.
Save
Share
Cite
Already a member? Login
